Literature DB >> 26733167

Downregulation of CD73 in 4T1 breast cancer cells through siRNA-loaded chitosan-lactate nanoparticles.

Farhad Jadidi-Niaragh1,2,3, Fatemeh Atyabi4,5, Ali Rastegari6, Esmail Mollarazi7, Melika Kiani6, Alireza Razavi1, Mehdi Yousefi2,3, Nasim Kheshtchin8, Hadi Hassannia1, Jamshid Hadjati8, Fazel Shokri9,10.   

Abstract

The immunosuppressive factors in tumor microenvironment enhance tumor growth and suppress anti-tumor immune responses. Adenosine is an important immunosuppressive factor which can be secreted by both tumor and immune cells trough action of two cell surface ecto-nucleotidase molecules CD39 and CD73. Blocking the adenosine generating molecules has emerged as an effective immunotherapeutic approach for treatment of cancer. In this study, CD73-siRNA encapsulated into chitosan-lactate (ChLa) nanoparticles (NPs) was employed to suppress the expression of CD73 molecule on 4T1 breast tumor cells, in vitro. ChLa NPs were generated through ionic gelation of ChLa by tripolyphosphate (TPP). Small interfering RNA (SiRNA)-loaded NPs had about 100 nm size with a polydispersive index below 0.3 and a zeta potential about 13. Our results showed that ChLa NPs with Ch 50 kDa exhibit the best physicochemical features with the high siRNA encapsulation capacity. Synthesized NPs were able to fully bind with siRNA, protect them against serum and heparin degradation, and promote the transfection process. While the NPs exhibited low toxicity during 72 h cell culture, the transfection of Ch-plasmid expressing green fluorescent protein (pEGFP) NPs was efficient in 4T1 cells with a transfection rate of 53.6 % as detected by flow cytometry. In addition, CD73-siRNA-loaded ChLa NPs could efficiently suppress the expression of CD73 as assayed by real-time polymerase chain reaction and flow cytometry. As a conclusion, CD73-siRNA-loaded ChLa NPs may be considered as a promising therapeutic tool for cancer therapy; however, further in vivo investigations are necessary.

Entities:  

Keywords:  CD73; Cancer; Nanoparticle; Treatment; siRNA

Mesh:

Substances:

Year:  2016        PMID: 26733167     DOI: 10.1007/s13277-015-4732-0

Source DB:  PubMed          Journal:  Tumour Biol        ISSN: 1010-4283


  41 in total

Review 1.  The skewed balance between Tregs and Th17 in chronic lymphocytic leukemia.

Authors:  Mehdi Yousefi; Ali Akbar Movassaghpour; Karim Shamsasenjan; Ghasem Ghalamfarsa; Sanam Sadreddini; Farhad Jadidi-Niaragh; Mohammad Hojjat-Farsangi
Journal:  Future Oncol       Date:  2015       Impact factor: 3.404

2.  Chitosan lactate as a nonviral gene delivery vector in COS-1 cells.

Authors:  Wanlop Weecharangsan; Praneet Opanasopit; Tanasait Ngawhirunpat; Theerasak Rojanarata; Auayporn Apirakaramwong
Journal:  AAPS PharmSciTech       Date:  2006-08-04       Impact factor: 3.246

3.  CD73 on tumor cells impairs antitumor T-cell responses: a novel mechanism of tumor-induced immune suppression.

Authors:  Dachuan Jin; Jie Fan; Long Wang; Linda F Thompson; Aijie Liu; Benjamin J Daniel; Tahiro Shin; Tyler J Curiel; Bin Zhang
Journal:  Cancer Res       Date:  2010-02-23       Impact factor: 12.701

4.  CD73 has distinct roles in nonhematopoietic and hematopoietic cells to promote tumor growth in mice.

Authors:  Long Wang; Jie Fan; Linda F Thompson; Yi Zhang; Tahiro Shin; Tyler J Curiel; Bin Zhang
Journal:  J Clin Invest       Date:  2011-05-02       Impact factor: 14.808

5.  Altered purinergic signaling in CD73-deficient mice inhibits tumor progression.

Authors:  Gennady G Yegutkin; Fumiko Marttila-Ichihara; Marika Karikoski; Jussi Niemelä; Juha P Laurila; Kati Elima; Sirpa Jalkanen; Marko Salmi
Journal:  Eur J Immunol       Date:  2011-05       Impact factor: 5.532

6.  In vitro cellular accumulation of gadolinium incorporated into chitosan nanoparticles designed for neutron-capture therapy of cancer.

Authors:  Futoshi Shikata; Hiroyuki Tokumitsu; Hideki Ichikawa; Yoshinobu Fukumori
Journal:  Eur J Pharm Biopharm       Date:  2002-01       Impact factor: 5.571

7.  RNA interference of ecto-5'-nucleotidase (CD73) inhibits human breast cancer cell growth and invasion.

Authors:  Xiuling Zhi; Sifeng Chen; Ping Zhou; Zhimin Shao; Li Wang; Zhouluo Ou; Lianhua Yin
Journal:  Clin Exp Metastasis       Date:  2007-06-21       Impact factor: 5.150

8.  Mesenchymal stem cells, MG63 and HEK293 transfection using chitosan-DNA nanoparticles.

Authors:  Karin Corsi; Fatiha Chellat; L'Hocine Yahia; Julio C Fernandes
Journal:  Biomaterials       Date:  2003-03       Impact factor: 12.479

9.  Thiolated chitosan nanoparticles as a delivery system for antisense therapy: evaluation against EGFR in T47D breast cancer cells.

Authors:  Fatemeh Talaei; Ebrahim Azizi; Rassoul Dinarvand; Fatemeh Atyabi
Journal:  Int J Nanomedicine       Date:  2011-09-14

Review 10.  Chitosan: An Update on Potential Biomedical and Pharmaceutical Applications.

Authors:  Randy Chi Fai Cheung; Tzi Bun Ng; Jack Ho Wong; Wai Yee Chan
Journal:  Mar Drugs       Date:  2015-08-14       Impact factor: 5.118

View more
  12 in total

Review 1.  S1PR1 as a Novel Promising Therapeutic Target in Cancer Therapy.

Authors:  Narges Rostami; Afshin Nikkhoo; Amir Ajjoolabady; Gholamreza Azizi; Mohammad Hojjat-Farsangi; Ghasem Ghalamfarsa; Bahman Yousefi; Mehdi Yousefi; Farhad Jadidi-Niaragh
Journal:  Mol Diagn Ther       Date:  2019-08       Impact factor: 4.074

2.  Inhibiting hepatic gluconeogenesis by chitosan lactate nanoparticles containing CRTC2 siRNA targeted by poly(ethylene glycol)-glycyrrhetinic acid.

Authors:  Ali Rastegari; Fatemeh Mottaghitalab; Rassoul Dinarvand; Mohsen Amini; Ehsan Arefian; Mahdi Gholami; Fatemeh Atyabi
Journal:  Drug Deliv Transl Res       Date:  2019-06       Impact factor: 4.617

3.  Dual Blockade of PD-1 and LAG3 Immune Checkpoints Increases Dendritic Cell Vaccine Mediated T Cell Responses in Breast Cancer Model.

Authors:  Asal Barshidi; Vahid Karpisheh; Fatemeh Karimian Noukabadi; Fariba Karoon Kiani; Mohammad Mohammadi; Negin Afsharimanesh; Farbod Ebrahimi; Seyed Hossein Kiaie; Jamshid Gholizadeh Navashenaq; Mohammad Hojjat-Farsangi; Naime Majidi Zolbanin; Ata Mahmoodpoor; Hadi Hassannia; Sanam Nami; Pooya Jalali; Reza Jafari; Farhad Jadidi-Niaragh
Journal:  Pharm Res       Date:  2022-06-17       Impact factor: 4.580

4.  CD73 downregulation by EGFR-targeted liposomal CD73 siRNA potentiates antitumor effect of liposomal doxorubicin in 4T1 tumor-bearing mice.

Authors:  Anvar Soleimani; Farshad Mirzavi; Sara Nikoofal-Sahlabadi; Amin Reza Nikpoor; Bita Taghizadeh; Mehdi Barati; Mohammad Soukhtanloo; Mahmoud Reza Jaafari
Journal:  Sci Rep       Date:  2022-06-21       Impact factor: 4.996

5.  Blockage of immune checkpoint molecules increases T-cell priming potential of dendritic cell vaccine.

Authors:  Hadi Hassannia; Mitra Ghasemi Chaleshtari; Fatemeh Atyabi; Mahshid Nosouhian; Ali Masjedi; Mohammad Hojjat-Farsangi; Afshin Namdar; Gholamreza Azizi; Hamed Mohammadi; Ghasem Ghalamfarsa; Gholamabas Sabz; Sajad Hasanzadeh; Mehdi Yousefi; Farhad Jadidi-Niaragh
Journal:  Immunology       Date:  2019-10-24       Impact factor: 7.397

Review 6.  Engineered nanoparticles induce cell apoptosis: potential for cancer therapy.

Authors:  Dan-Dan Ma; Wan-Xi Yang
Journal:  Oncotarget       Date:  2016-06-28

7.  Antitumor effect of hyaluronic-acid-modified chitosan nanoparticles loaded with siRNA for targeted therapy for non-small cell lung cancer.

Authors:  Wenhua Zhang; Wenhua Xu; Yu Lan; Xuliang He; Kaibin Liu; Ye Liang
Journal:  Int J Nanomedicine       Date:  2019-07-15

Review 8.  Engineering Nanoparticles for Targeted Delivery of Nucleic Acid Therapeutics in Tumor.

Authors:  Yao Xiao; Kun Shi; Ying Qu; Bingyang Chu; Zhiyong Qian
Journal:  Mol Ther Methods Clin Dev       Date:  2018-09-22       Impact factor: 6.698

9.  Targeted Co-Delivery of Docetaxel and cMET siRNA for Treatment of Mucin1 Overexpressing Breast Cancer Cells.

Authors:  Naime Majidi Zolbanin; Reza Jafari; Jafar Majidi; Fatemeh Atyabi; Mehdi Yousefi; Farhad Jadidi-Niaragh; Leili Aghebati-Maleki; Dariush Shanehbandi; Mohammad-Sadegh Soltani Zangbar; Alireza Mohajjel Nayebi
Journal:  Adv Pharm Bull       Date:  2018-08-29

Review 10.  Adenosine Blockage in Tumor Microenvironment and Improvement of Cancer Immunotherapy.

Authors:  Samaneh Arab; Jamshid Hadjati
Journal:  Immune Netw       Date:  2019-08-27       Impact factor: 6.303

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.